Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
binodenoson · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| binodenoson then adenosine | OTHER | binodenoson (experimental); adenosine (active comparator) |
| adenosine then binodenoson | OTHER | adenosine (active comparator); binodenoson (experimental) |
| adenosine then adenosine | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| binodenoson | DRUG | 30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo |
| adenosine | DRUG | 30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute) |
Inclusion Criteria: * Able to understand and sign an informed consent form. Exclusion Criteria: * Women who are of childbearing potential. * Very low likelihood of coronary artery disease (by American Heart Association and American College of Cardiology standards). * Documented history of acute m...
Binodenoson is an investigational small molecule being developed for use in Coronary Artery Disease. It is intended to assess cardiac ischemia, as studied in two Phase 3 clinical trials. The drug is not yet approved and remains in clinical development.
Binodenoson is a small molecule that acts as a coronary vasodilator. It is being studied for its ability to assess cardiac ischemia in patients with Coronary Artery Disease. The specific molecular target has not been disclosed in the available information.
Binodenoson is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for Coronary Artery Disease.
Binodenoson is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug is not yet available on the market.
Binodenoson has been studied in two completed Phase 3 trials: NCT00944294 and NCT00944970. Both trials assessed the efficacy and safety of binodenoson in evaluating cardiac ischemia in patients with Coronary Artery Disease, with a combined enrollment of 997 participants.
Binodenoson is a distinct investigational compound developed by Pfizer. No alternative names have been reported for this drug in the available information. It is being studied specifically for its role in assessing cardiac ischemia in Coronary Artery Disease.